| Literature DB >> 34831236 |
Lukasz Szczerbinski1,2, Mark Alan Taylor2,3, Urszula Puchta1, Paulina Konopka2, Adam Paszko2, Anna Citko2, Karol Szczerbinski1, Joanna Goscik2, Maria Gorska1, Steen Larsen2,4, Adam Kretowski1,2.
Abstract
BACKGROUND: Mitochondrial dysfunction has been implicated in the pathogenesis of type 2 diabetes, but its contribution to the early stages of dysglycemia remains poorly understood. By collecting a high-resolution stage-based spectrum of dysglycemia, our study fills this gap by evaluating derangement in both the function and quantity of mitochondria. We sampled mitochondria in skeletal muscle and subcutaneous adipose tissues of subjects with progressive advancement of dysglycemia under a three-month exercise intervention.Entities:
Keywords: adipose tissue; exercise; fat; mitochondria; muscle; obesity; prediabetes; type 2 diabetes
Mesh:
Year: 2021 PMID: 34831236 PMCID: PMC8616473 DOI: 10.3390/cells10113013
Source DB: PubMed Journal: Cells ISSN: 2073-4409 Impact factor: 6.600
Figure 1Schematic diagram of the project design and description of each patients’ visit to the study center. OGTT—oral glucose tolerance test.
Inclusion and exclusion criteria for study participants.
| Inclusion Criteria | Exclusion Criteria |
|---|---|
|
Age: 35–65 years old BMI: 25–35 kg/m2 Male gender Ability of performing exercise training Sedentary lifestyle assessed using the Polish version of International Physical Activity Questionnaire—Long Form (IPAQ-LF) [ |
Smoking Drug or alcohol addiction Any chronic disease (exceptions: hypertension, obesity with BMI ≤ 35 kg/m2, type 2 diabetes) Any chronic medications (exceptions: angiotensin-converting-enzyme inhibitors for hypertension and metformin in type 2 diabetics) Highly active lifestyle Medical contraindications to participate in planned exercise sessions |
Clinical characteristics of studied participants. Presented are mean values and interquartile ranges for each parameter. IFG-subjects with impaired fasting glucose and normal glucose tolerance; IFG+IGT–subjects with impaired fasting glucose and impaired glucose tolerance; BMI–body mass index; HbA1c-Haemoglobin A1c; VAT–visceral adipose tissue; TG–triglycerides; HDL-high-density lipoprotein cholesterol; LDL-low-density lipoprotein cholesterol; VO2max-maximal oxygen consumption; HOMA-IR-homeostatic model assessment for insulin resistance was calculated; HOMA-β-homeostatic model assessment of beta-cell function. Bold and Italic values denote statistical significance at the p < 0.05 level.
| Parameter (Unit) | Normoglycemia | IFG | IFG + IGT | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Before | After 3 m. | Before | After 3 m. | Before | After 3 m. | Baseline | Time | Time × Diagnosis | |
|
| 89.43 | 89.30 | 92.80 | 91.69 | 95.60 | 93.57 | 0.557 |
| 0.272 |
| (83.84–95.02) | (83.70–94.89) | (88.20–97.40) | (87.09–96.30) | (87.07–104.14) | (85.01–102.13) | ||||
|
| 27.62 | 27.55 | 29.37 | 29.00 | 31.98 | 31.31 |
|
| 0.288 |
| (26.08–29.17) | (26.00–29.09) | (28.09–30.64) | (27.73–30.28) | (29.62–34.34) | (28.94–33.69) | ||||
|
| 5.24 | 5.12 | 5.46 | 5.31 | 5.76 | 5.61 |
|
| 0.881 |
| (5.06–5.42) | (4.94–5.30) | (5.32–5.61) | (5.16–5.46) | (5.49–6.03) | (5.33–5.88) | ||||
|
| 96.14 | 101.19 | 109.50 | 105.26 | 120.19 | 110.70 |
| 0.148 |
|
| (99.15–93.32) | (104.60–98) | (112.72–106.46) | (108.29–102.40) | (127.59–113.60) | (117.36–104.76) | ||||
|
| 85.76 | 98.79 | 96.10 | 92.09 | 165.88 | 116.15 |
|
|
|
| (75.14–97.08) | (87.19–111.11) | (86.74–105.93) | (82.82–101.86) | (143.36–190.04) | (96.61–137.47) | ||||
|
| 9.44 | 9.28 | 12.32 | 10.37 | 21.07 | 15.60 |
|
|
|
| (7.23–11.66) | (7.06–11.49) | (10.48–14.15) | (8.54–12.21) | (17.28–24.87) | (11.62–19.57) | ||||
|
| 18.23 | 19.79 | 36.36 | 22.69 | 178.29 | 82.96 |
|
|
|
| (12.13–27.40) | (13.09–29.91) | (25.99–50.87) | (16.16–31.87) | (88.88–357.62) | (39.9–172.50) | ||||
|
| 1.55 | 1.46 | 1.80 | 1.57 | 2.59 | 2.19 |
|
| 0.075 |
| (1.24–1.88) | (1.16–1.79) | (1.52–2.09) | (1.32–1.85) | (2.00–3.26) | (1.65–2.82) | ||||
|
| 193.29 | 194.11 | 194.64 | 200.66 | 206.29 | 196.01 | 0.879 | 0.762 | 0.258 |
| (175.80–210.79) | (176.48–211.74) | (180.22–209.06) | (186.15–215.18) | (179.56–233.02) | (168.67–223.35) | ||||
|
| 98.44 | 89.79 | 102.07 | 104.72 | 151.66 | 125.88 | 0.166 | 0.086 | 0.184 |
| (78.50–123.45) | (71.48–112.79) | (84.70–123.01) | (86.80–126.35) | (107.32–214.33) | (88.39–179.28) | ||||
|
| 56.20 | 57.19 | 50.54 | 50.27 | 53.33 | 52.38 | 0.258 | 0.933 | 0.745 |
| (50.25–62.49) | (51.16–63.57) | (45.87–55.43) | (45.60–55.17) | (44.62–62.82) | (43.62–61.94) | ||||
|
| 122.09 | 124.88 | 131.03 | 131.84 | 130.72 | 134.24 | 0.684 | 0.509 | 0.936 |
| (106.35–137.82) | (109.01–140.75) | (118.06–144.00) | (118.77–144.90) | (106.67–154.77) | (109.59–158.89) | ||||
|
| 32.33 | 32.65 | 30.44 | 32.20 | 29.07 | 31.26 | 0.427 | 0.221 |
|
| (31.18–35.48) | (31.46–35.83) | (28.66–32.22) | (30.40–34.00) | (25.78–32.36) | (27.85–34.68) | ||||
|
| 2.07 | 2.13 | 3.13 | 2.46 | 5.95 | 4.25 |
|
|
|
| (1.70–2.53) | (1.75–2.60) | (2.66–3.69) | (2.09–2.90) | (4.23–8.37) | (2.96–6.09) | ||||
|
| 95.75 | 80.84 | 90.42 | 81.05 | 130.24 | 105.04 | 0.146 |
| 0.729 |
| (79.92–114.71) | (67.47–96.85) | (77.88–105.00) | (69.80–94.11) | (95.58–177.46) | (75.69–145.77) | ||||
|
| 25.17 | 24.49 | 28.01 | 26.02 | 31.33 | 28.62 | 0.237 |
| 0.136 |
| (21.84–28.51) | (21.14–27.83) | (25.26–30.76) | (23.26–28.77) | (26.24–36.43) | (23.49–33.75) | ||||
|
| 60.46 | 61.64 | 61.18 | 62.39 | 59.78 | 60.74 | 0.835 |
| 0.883 |
| (57.30–63.61) | (58.48–64.80) | (58.58–63.78) | (59.79–65.00) | (54.96–64.61) | (55.91–65.57) | ||||
Figure 2MUSCLE mitochondrial content (via citrate synthase activity) and mass-specific respiratory capacity parameters in patients with Normoglycemia (NG), isolated Impaired Fasting Glucose (IFG) and Impaired Fasting Glucose and Impaired Glucose Tolerance (IFG + IGT), before and after 3 months of exercise intervention. (A). Complex I-linked OXPHOS capacity (CIP); (B). Maximal complex I + II-linked OXPHOS capacity (CI + IIP), (C). maximal capacity of the electron transfer system (ETSmax); (D). Km for succinate titration, (E). Citrate Synthase (CS) activity. (F). β-hydroxy-acyl-CoA dehydrogenase (HAD) activity. Square root transformation was performed to calculate model-based means and 95% CI.
Figure 3Pairwise correlations among clinical features and parameters of mitochondrial respiration in skeletal muscle. (A). Correlation between Citrate Synthase (CS) activity and Body Mass Index (BMI). (B). Correlation between Citrate Synthase (CS) activity and glucose concentration at 120-min of OGTT (glucose-120′). (C). Correlation between changes in Km for succinate titration and changes in VO2max under the intervention.* means multiplication.
Figure 4ADIPOSE TISSUE mitochondrial content (via citrate synthase activity) and mass-specific respiratory capacity parameters in patients with Normoglycemia (NG), isolated Impaired Fasting Glucose (IFG) and Impaired Fasting Glucose and Impaired Glucose Tolerance (IFG + IGT), before and after 3 months of exercise intervention. (A). Complex I-linked OXPHOS capacity (CIP); (B). Maximal complex I + II -linked OXPHOS capacity (CI + IIP), (C). maximal capacity of the electron transfer system (ETSmax); (D). Km for succinate titration, (E). Citrate Synthase (CS) activity. (F). β-hydroxy-acyl-CoA dehydrogenase (HAD) activity. Square root transformation was performed to calculate model-based means and 95% CI.